ASLAN Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
April 27, 2022 07:00 ET
|
ASLAN PHARMACEUTICALS LIMITED
Global Phase 2b trial for eblasakimab in moderate-to-severe atopic dermatitis (AD) progressing, multiple sites enrolling; topline data expected in the first half of 2023Alex Kaoukhov, MD, appointed as...